CINCINNATI, Sept. 29 /PRNewswire-FirstCall/ -- Kendle, a leading global full-service clinical research organization (CRO), today announced Michael Lawson has joined the company as Director, Investor Relations. Lawson is responsible for expanding the company's investor relations program to strengthen shareholder and analyst relations and ultimately grow the company's shareholder base. Lawson is based in Cincinnati and reports to Karl "Buzz" Brenkert III, Senior Vice President and Chief Financial Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )
"Mike's experience in working with buy-side and sell-side analysts, along with his expertise in developing and executing targeted financial communications strategies, will be of great benefit to Kendle as we focus on sharing the Kendle story with current and potential analysts and shareholders," said Buzz Brenkert, Senior Vice President and CFO.
Lawson brings more than two decades of investor relations and corporate communications experience to his position with Kendle. Most recently, he served as Vice President of Investor Relations for Associated Estates Realty Corporation, a multi-family real estate investment trust in Cleveland. His experience also includes serving as Director of Investor Relations and Corporate Communications for Granite Construction Incorporated in Watsonville, Calif., one of the largest transportation builders in the country. Lawson began his career working as a journalist for The McGraw-Hill Companies.
About Kendle
Kendle International Inc. is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at http://www.kendle.com/.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk,
